trustme.bro/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim
Procrit causes lethal side effects
the verdict
CONTESTED
contested - evenly split
refutedsupported
the weight of evidence
2 sources for · 2 against

The safety profile of Procrit (epoetin alfa) remains a subject of ongoing clinical debate, with some studies pointing to cardiovascular risks and potential mortality concerns, while others report acceptable safety and manageable side effects in clinical practice.

The evidence we hold leans evenly split

How this was weighed

official record 3x · fact-check 2x · hedged 1x · crowd & reference 1x

  • Mortality Risk of Darbepoetin Alfa versus Epoetin Alfa in Pa · peer-reviewed · supports · weight 1.3 · 2015
  • Personalized Therapeutic Advances in Erythropoietin Signalin · peer-reviewed · supports · weight 1.05 · 2025
  • Erythropoiesis-Stimulating Agents in the Management of Anemi · peer-reviewed · refutes · weight 1.3 · 2018
  • Efficacy and safety of recombinant human erythropoietin (Hem · peer-reviewed · refutes · weight 1.05 · 2021
Evidence for · 2
Mortality Risk of Darbepoetin Alfa versus Epoetin Alfa in Patients with Chronic Kidney Disease: Systematic Review and Meta-Analysis
2015 · cited by 48
Paper 0 notes that while overall mortality differences were not significant in certain analyses, the confidence intervals remained wide and compatible with considerable harm from erythropoiesis-stimulating agents.
Evidence against · 2
Erythropoiesis-Stimulating Agents in the Management of Anemia in Chronic Kidney Disease or Cancer: A Historical Perspective.
2018 · cited by 24
Paper 1 discusses how many previous concerns regarding safety have been addressed by the reassuring results of post-approval studies.
See more details
The analysis

The retrieved papers present mixed findings regarding the safety of erythropoiesis-stimulating agents like Procrit (epoetin alfa). Some sources highlight safety concerns, cardiovascular risks, and potential mortality harms, while other clinical trials and reviews emphasize reassuring post-approval data and acceptable safety profiles. This division of evidence across the provided literature warrants a CONTESTED verdict.

More for · 1
Personalized Therapeutic Advances in Erythropoietin Signaling: From Anemia Management to Extensive Clinical Applications.
2025 · cited by 6
Paper 6 notes that emerging evidence highlights both therapeutic opportunities and significant risks, including cardiovascular complications associated with EPO signaling.
More against · 1
Efficacy and safety of recombinant human erythropoietin (Hema-Plus®) for management of anemia in Thai patients on peritoneal dialysis
2021 · cited by 8
Paper 4 concludes that epoetin alfa effectively increased hemoglobin levels with an acceptable safety profile.
The paper trail · every fact has a biography
first checked04 Aug 2026
judged → CONTESTED · 3704 Aug 2026
This receipt carries no identity, shared or not. Sharing publishes your connection to it, not your data.
Check your own claim
Challenge the receipt
trust me, bro: win the argument, pass the class, survive peer review.
This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work · Dispute this receipt